rifampin

Summary

Summary: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Top Publications

  1. pmc Rapid molecular detection of tuberculosis and rifampin resistance
    Catharina C Boehme
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    N Engl J Med 363:1005-15. 2010
  2. pmc Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study
    Catharina C Boehme
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    Lancet 377:1495-505. 2011
  3. pmc Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology
    Danica Helb
    Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey 07103, USA
    J Clin Microbiol 48:229-37. 2010
  4. pmc Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    PLoS Med 8:e1001067. 2011
  5. ncbi Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting
    Grant Theron
    Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 184:132-40. 2011
  6. ncbi Structural mechanism for rifampicin inhibition of bacterial rna polymerase
    E A Campbell
    The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Cell 104:901-12. 2001
  7. ncbi Prosthetic-joint infections
    Werner Zimmerli
    Basel University Medical Clinic, Kantonsspital, Liestal, Switzerland
    N Engl J Med 351:1645-54. 2004
  8. pmc Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis
    Patricia J Campbell
    Mycobacteriology Laboratory Branch, Division of Tuberculosis Elimination, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Bldg 17, Room 4029, M S F08, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 55:2032-41. 2011
  9. ncbi Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial
    Willemien A Nienhuis
    Department of Internal Medicine, University Medical Centre Groningen, University of Groningen, Netherlands
    Lancet 375:664-72. 2010
  10. pmc Evaluation of the analytical performance of the Xpert MTB/RIF assay
    Robert Blakemore
    Division of Infectious Disease, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ 07103, USA
    J Clin Microbiol 48:2495-501. 2010

Detail Information

Publications370 found, 100 shown here

  1. pmc Rapid molecular detection of tuberculosis and rifampin resistance
    Catharina C Boehme
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    N Engl J Med 363:1005-15. 2010
    ..Early detection is essential to reduce the death rate and interrupt transmission, but the complexity and infrastructure needs of sensitive methods limit their accessibility and effect...
  2. pmc Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study
    Catharina C Boehme
    Foundation for Innovative New Diagnostics, Geneva, Switzerland
    Lancet 377:1495-505. 2011
    ..We aimed to assess operational feasibility, accuracy, and effectiveness of implementation in such settings...
  3. pmc Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology
    Danica Helb
    Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey 07103, USA
    J Clin Microbiol 48:229-37. 2010
    ..tuberculosis and rifampin resistance. Analytic tests of M. tuberculosis DNA demonstrated a limit of detection (LOD) of 4...
  4. pmc Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
    PLoS Med 8:e1001067. 2011
    ..However, its utility for routine TB screening and detection of rifampicin resistance among HIV-infected patients with advanced immunodeficiency enrolling in antiretroviral therapy (ART) services is unknown...
  5. ncbi Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting
    Grant Theron
    Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Am J Respir Crit Care Med 184:132-40. 2011
    ..Xpert MTB/RIF is a novel automated molecular diagnostic recently endorsed by the World Health Organization. However, performance-related data from high HIV prevalence settings are limited...
  6. ncbi Structural mechanism for rifampicin inhibition of bacterial rna polymerase
    E A Campbell
    The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Cell 104:901-12. 2001
    ..The structure, combined with biochemical results, explains the effects of Rif on RNAP function and indicates that the inhibitor acts by directly blocking the path of the elongating RNA when the transcript becomes 2 to 3 nt in length...
  7. ncbi Prosthetic-joint infections
    Werner Zimmerli
    Basel University Medical Clinic, Kantonsspital, Liestal, Switzerland
    N Engl J Med 351:1645-54. 2004
  8. pmc Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis
    Patricia J Campbell
    Mycobacteriology Laboratory Branch, Division of Tuberculosis Elimination, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Bldg 17, Room 4029, M S F08, Atlanta, GA 30333, USA
    Antimicrob Agents Chemother 55:2032-41. 2011
    ..We used DNA sequencing to detect resistance to the first-line antituberculosis drugs isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB) and the second-line drugs amikacin (AMK), capreomycin (CAP), ..
  9. ncbi Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial
    Willemien A Nienhuis
    Department of Internal Medicine, University Medical Centre Groningen, University of Groningen, Netherlands
    Lancet 375:664-72. 2010
    ..These recommendations were based on observational studies and a small pilot study with microbiological endpoints. We investigated the efficacy of two regimens of antimicrobial treatment in early-stage M ulcerans infection...
  10. pmc Evaluation of the analytical performance of the Xpert MTB/RIF assay
    Robert Blakemore
    Division of Infectious Disease, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ 07103, USA
    J Clin Microbiol 48:2495-501. 2010
    ..MTB/RIF assay, a nucleic acid amplification-based diagnostic system that detects Mycobacterium tuberculosis and rifampin (RIF) resistance in under 2 h...
  11. ncbi Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries
    M A Espinal
    World Health Organization, Communicable Diseases Programme, Ave Appia 20, 1211 Geneva 27, Switzerland
    JAMA 283:2537-45. 2000
    ....
  12. pmc Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory 7925, Cape Town, South Africa
    Future Microbiol 6:1067-82. 2011
    ..Following endorsement by the WHO in 2010, we consider the next steps in the implementation of the assay and its potential impact in high burden settings...
  13. ncbi Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
    A Telenti
    Institute for Medical Microbiology, University of Berne, Switzerland
    Lancet 341:647-50. 1993
    ..These findings provide the basis for rapid detection of rifampicin resistance, a marker of multidrug-resistant tuberculosis...
  14. pmc The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study
    Ted Cohen
    Division of Global Health Equity, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 7:e1000296. 2010
    ..We conducted limited autopsies on young adults dying in a single public hospital in the province of KwaZulu-Natal between October 2008 and August 2009 in order to estimate the magnitude of deaths attributable to tuberculosis...
  15. pmc Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission
    M De Vos
    DST NRF Centre of Excellence for Biomedical Tuberculosis Research MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa
    Antimicrob Agents Chemother 57:827-32. 2013
    b>Rifampin resistance in clinical isolates of Mycobacterium tuberculosis arises primarily through the selection of bacterial variants harboring mutations in the 81-bp rifampin resistance-determining region of the rpoB gene...
  16. pmc Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease
    Fred Stephen Sarfo
    Komfo Anokye Teaching Hospital, Kumasi, Ghana
    Antimicrob Agents Chemother 54:3678-85. 2010
    We have evaluated the clinical efficacy of the combination of oral rifampin at 10 mg/kg of body weight and intramuscular streptomycin at 15 mg/kg for 8 weeks (RS8), as recommended by the WHO, in 160 PCR-confirmed cases of Mycobacterium ..
  17. ncbi Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa
    Marinus Barnard
    Foundation for Innovative New Diagnostics, 71 av Louis Casai, 1216 Cointrin, Switzerland
    Am J Respir Crit Care Med 177:787-92. 2008
    ..Conventional methods for detecting Mycobacterium tuberculosis drug resistance take weeks to months to produce results. Rapid molecular testing for drug resistance is available but has not been implemented in high-TB-burden settings...
  18. pmc The impact and cost of scaling up GeneXpert MTB/RIF in South Africa
    Gesine Meyer-Rath
    Health Economics and Epidemiology Research Office HE2RO, Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
    PLoS ONE 7:e36966. 2012
    ....
  19. ncbi Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group
    W Zimmerli
    Department of Internal Medicine, University Hospitals, Basel, Switzerland
    JAMA 279:1537-41. 1998
    b>Rifampin-containing regimens are able to cure staphylococcal implant-related infections based on in vitro and in vivo observations. However, this evidence has not been proven by a controlled clinical trial.
  20. pmc Evolution of Escherichia coli rifampicin resistance in an antibiotic-free environment during thermal stress
    Alejandra Rodríguez-Verdugo
    Department of Ecology and Evolutionary Biology, UC Irvine, Irvine, CA, USA
    BMC Evol Biol 13:50. 2013
    ..2°c)...
  21. pmc Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study
    Andrea Rachow
    Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich LMU, Munich, Germany
    PLoS ONE 6:e20458. 2011
    ....
  22. pmc Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease)
    Kapay Kibadi
    Programme National de Lutte contre l Ulcère de Buruli, Kinshasa, Democratic Republic of the Congo
    PLoS Negl Trop Dis 4:e736. 2010
    ..We evaluated the effectiveness of this strategy in a series of patients with large ulcers of > or =10 cm in longest diameter in a rural health zone of the Democratic Republic of Congo (DRC)...
  23. ncbi Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis
    Faiz A Khan
    Montreal Chest Institute, McGill University Health Centre, Montreal, Canada
    Clin Infect Dis 50:1288-99. 2010
    ..Patients with human immunodeficiency virus (HIV) infection and tuberculosis have an increased risk of death, treatment failure, and relapse...
  24. ncbi The competitive cost of antibiotic resistance in Mycobacterium tuberculosis
    Sebastien Gagneux
    Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA 94305, USA
    Science 312:1944-6. 2006
    ..We show that in laboratory-derived mutants of Mycobacterium tuberculosis, rifampin resistance is universally associated with a competitive fitness cost and that this cost is determined by the ..
  25. pmc Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
    Marcus B Conde
    Instituto de Doencas do Torax Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
    Lancet 373:1183-9. 2009
    ..The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the initial stage of tuberculosis treatment...
  26. ncbi Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin
    A Geick
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
    J Biol Chem 276:14581-7. 2001
    ..In addition to genetic factors, exposure to drugs such as rifampin can profoundly affect its expression...
  27. ncbi Use of the rpoB gene to determine the specificity of base substitution mutations on the Escherichia coli chromosome
    Lilit Garibyan
    Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA
    DNA Repair (Amst) 2:593-608. 2003
    ..Because of the conservation of key regions of RNA polymerase among many microorganisms, using the Rif(r)/rpoB system may be a general method for studying mutational processes in microorganisms without well developed genetic systems...
  28. ncbi Antituberculosis drugs and hepatotoxicity
    Wing Wai Yew
    Tuberculosis and Chest Unit, Grantham Hospital, Hong Kong, China
    Respirology 11:699-707. 2006
    ..Monitoring of liver chemistry is also required for those patients at risk of drug-induced hepatotoxicity...
  29. pmc Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection
    Teresa G Martins
    Life and Health Sciences Research Institute ICVS, School of Health Sciences, University of Minho, Braga, Portugal
    PLoS ONE 7:e32740. 2012
    ..Histological analysis of human tissue samples suggests that such antibiotic treatment reverses the mycolactone-induced local immunosuppression, leading to increased inflammatory infiltrations and phagocytosis of bacilli...
  30. pmc Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
    Paul J Converse
    Johns Hopkins University Center for Tuberculosis Research, 1551 Jefferson Street, 154, Baltimore, MD 21287, USA
    Future Microbiol 6:1185-98. 2011
    ..Based on promising preclinical studies, treatment trials in West Africa have shown that a combination of rifampin and streptomycin administered daily for 8 weeks can kill M...
  31. pmc Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda
    Hamidou Traore
    London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Ann Clin Microbiol Antimicrob 6:1. 2007
    ..tuberculosis isolates for resistance to rifampicin. The purpose of this study was to investigate the performance of this technology in Kampala, Uganda...
  32. ncbi Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial
    A Jindani
    International Union Against Tuberculosis and Lung Disease, 68 boulevard Saint Michel, 75006 Paris, France
    Lancet 364:1244-51. 2004
    ..A WHO-recommended 8-month regimen based on ethambutol and isoniazid was evaluated in a randomised clinical trial against a 6-month standard regimen...
  33. ncbi Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?
    A Trebucq
    Institute of International Union Against Tuberculosis and Lung Disease, Paris, France
    Int J Tuberc Lung Dis 15:1567-72. 2011
    ..The assay should be widely used for this purpose if, and only if, excellent MDR-TB management is available, both for ethical reasons and to reduce the risk of extensively drug-resistant TB...
  34. pmc Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study
    Lesley E Scott
    Department of Molecular Medicine and Hematology, University of the Witwatersrand, Johannesburg, South Africa
    PLoS Med 8:e1001061. 2011
    ....
  35. ncbi Epistasis buffers the fitness effects of rifampicin- resistance mutations in Pseudomonas aeruginosa
    Alex R Hall
    Department of Zoology, University of Oxford, South Parks Road, Oxford OX1 3PS, UK
    Evolution 65:2370-9. 2011
    ..These results suggest that antagonistic epistasis between intragenic resistance mutations may be a key determinant of the cost of antibiotic resistance and compensatory adaptation in pathogen populations...
  36. pmc Rifampin drug resistance tests for tuberculosis: challenging the gold standard
    Armand van Deun
    Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium
    J Clin Microbiol 51:2633-40. 2013
    The rapid diagnosis of rifampin resistance is hampered by a reported insufficient specificity of molecular techniques for detection of rpoB mutations...
  37. pmc Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampin-resistant, rpoB mutant Mycobacterium tuberculosis
    Gregory P Bisson
    Division of Infectious Diseases, Department of Medicine, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Bacteriol 194:6441-52. 2012
    Multidrug-resistant tuberculosis has emerged as a major threat to tuberculosis control. Phylogenetically related rifampin-resistant actinomycetes with mutations mapping to clinically dominant Mycobacterium tuberculosis mutations in the ..
  38. ncbi Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling
    Joanna C Betts
    Respiratory Pathogens, GlaxoSmithKline, Stevenage, Herts, UK
    Mol Microbiol 43:717-31. 2002
    ..Thus, we have generated a model with which we can search for agents active against persistent M. tuberculosis and revealed a number of potential targets expressed under these conditions...
  39. pmc High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital
    Scott R Curry
    Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Infect Dis 48:425-9. 2009
    b>Rifampin is used as adjunctive therapy for Clostridium difficile-associated disease, and the drug's derivative, rifaximin, has emerged as an attractive antimicrobial for treatment of C. difficile-associated disease...
  40. ncbi Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa
    Joanna Evans
    Division of Medical Microbiology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    J Antimicrob Chemother 63:11-6. 2009
    ..To evaluate the efficacy of such assays in this setting, the GenoType MTBDRplus assay (HAIN Lifescience) and multiplex allele-specific PCR assays were carried out...
  41. pmc Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay
    S G Franzblau
    GWL Hansen s Disease Center, Baton Rouge, Louisiana 70894, USA
    J Clin Microbiol 36:362-6. 1998
    ..A colorimetric, microplate-based Alamar Blue assay (MABA) method was used to determine the MICs of isoniazid (INH), rifampin, streptomycin (SM), and ethambutol (EMB) for 34 Peruvian Mycobacterium tuberculosis isolates (including both ..
  42. pmc Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)
    Annick Chauty
    Centrr de Dépistage et de Traitement de l ulcère de Buruli, Pobè, Benin
    Antimicrob Agents Chemother 51:4029-35. 2007
    ..of the 6th WHO Advisory Committee on Buruli ulcer, directly observed treatment with the combination of rifampin and streptomycin, administered daily for 8 weeks, was recommended to 310 patients diagnosed with Buruli ulcer in ..
  43. pmc Compensatory evolution in rifampin-resistant Escherichia coli
    M G Reynolds
    Department of Biology, Emory University, Atlanta, Georgia 30322, USA
    Genetics 156:1471-81. 2000
    This study examines the intrinsic fitness burden associated with RNA polymerase (rpoB) mutations conferring rifampin resistance in Escherichia coli K12 (MG1655) and explores the nature of adaptation to the costs of resistance...
  44. pmc Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis
    Freddie Bwanga
    Department of Medical Microbiology Makerere University College of Health Sciences Kampala, Uganda
    BMC Infect Dis 9:67. 2009
    ....
  45. pmc Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis
    Dick Menzies
    Respiratory and Epidemiology Clinical Research Unit, Montreal Chest Institute and Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada
    PLoS Med 6:e1000146. 2009
    Treatment regimens for active tuberculosis (TB) that are intermittent, or use rifampin during only the initial phase, offer practical advantages, but their efficacy has been questioned...
  46. pmc Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results
    Panayotis Ioannidis
    National Reference Laboratory for Mycobacteria NRLM, SOTIRIA Chest Diseases Hospital, Mesogion 152, 11527 Athens, Greece
    J Clin Microbiol 49:3068-70. 2011
    ..3%, 93%, 79%, and 95.6%. The assay correctly detected rifampin resistance in all but one specimen, which harbored a mixed population...
  47. pmc Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens
    Sylvie Armand
    CHU Lille, F 59000 Lille, France
    J Clin Microbiol 49:1772-6. 2011
    ..Among the 97 culture-positive specimens, 4 had rifampin-resistant isolates...
  48. pmc Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice
    Deepak Almeida
    Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS Negl Trop Dis 5:e933. 2011
    ..ulcerans disease, or Buruli ulcer (BU), has shifted from surgery to treatment with streptomycin(STR)+rifampin(RIF) since 2004 based on studies in a mouse model and clinical trials...
  49. ncbi Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance
    D J Jin
    Department of Bacteriology, University of Wisconsin, Madison 53706
    J Mol Biol 202:45-58. 1988
    ..These alleles are located in three distinct clusters in the center of the rpoB gene. We discuss the implications of our results with regards to the structure of the rifampicin binding site...
  50. pmc Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers
    C J L la Porte
    Department of Clinical Pharmacy, University Medical Centre Nijmegen, Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 48:1553-60. 2004
    ..protease inhibitor, at the standard dose (400/100 mg twice a day [BID]) with the antituberculous agent rifampin is contraindicated because of a significant pharmacokinetic interaction due to induction of cytochrome P450 3A by ..
  51. pmc Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results
    A Van Deun
    Mycobacteriology Unit, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerp, Belgium
    J Clin Microbiol 47:3501-6. 2009
    The objectives of this study were to investigate the origin of highly discordant rifampin (rifampicin) (RMP) drug susceptibility test results obtained for Mycobacterium tuberculosis strains during proficiency testing...
  52. pmc Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis
    Deneke H Mariam
    Department of Bacteriology, Swedish Institute for Infectious Disease Control, S 171 82 Solna, Sweden
    Antimicrob Agents Chemother 48:1289-94. 2004
    b>Rifampin is a major drug used in the treatment of tuberculosis infections, and increasing rifampin resistance represents a worldwide clinical problem...
  53. pmc Transformation of Rickettsia prowazekii to rifampin resistance
    L I Rachek
    Department of Microbiology and Immunology, University of South Alabama College of Medicine, Mobile 36688, USA
    J Bacteriol 180:2118-24. 1998
    ..in this organism, we identified a specific mutation in the rickettsial rpoB gene that confers resistance to rifampin and used it to demonstrate allelic exchange in R. prowazekii...
  54. pmc Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus
    Azzam Saleh-Mghir
    Département de Médecine Aiguë Spécialisée, Hopital Raymond Poincare, 104 boulevard Raymond Poincaré, 92380 Garches Cedex, France
    Antimicrob Agents Chemother 55:4589-93. 2011
    ..m.] twice daily [b.i.d.]), both either alone or with adjunctive rifampin (10 mg/kg i.m. b.i.d.)...
  55. ncbi Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy
    Awewura Kwara
    The Miriam Hospital, Providence, Rhode Island 02906, USA
    AIDS 25:388-90. 2011
    Some individuals have higher efavirenz plasma concentrations during rifampin-containing tuberculosis (TB) therapy, contrary to the expected induction effect of rifampin...
  56. ncbi Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000
    Jiehui Li
    Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, New York, NY 10007, USA
    Clin Infect Dis 41:83-91. 2005
    The relationship between rifamycin use and either relapse or treatment failure with acquired rifampin resistance (ARR) among human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB) is not well understood.
  57. ncbi Pharmacokinetic interactions with rifampicin : clinical relevance
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacokinet 42:819-50. 2003
    The antituberculosis drug rifampicin (rifampin) induces a number of drug-metabolising enzymes, having the greatest effects on the expression of cytochrome P450 (CYP) 3A4 in the liver and in the small intestine...
  58. ncbi Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy
    Laarni G Villahermosa
    Leonard Wood Memorial Center for Leprosy Research, Cebu, The Philippines
    Am J Trop Med Hyg 70:197-200. 2004
    Monthly doses of rifampin, ofloxacin, and minocycline (ROM) are expected to be effective treatment for multi-bacillary leprosy. Patients with MB leprosy received ROM (n = 10) or World Health Organization multi-drug therapy (MDT) (n = 11)...
  59. ncbi A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes
    W M El-Sadr
    Division of Infectious Diseases, Harlem Hospital Center and Columbia University, College of Physicians and Surgeons, New York, NY 10037, USA
    Clin Infect Dis 32:623-32. 2001
    Six-month regimens that include rifampin for the treatment of tuberculosis in patients without human immunodeficiency virus (HIV) infection are recommended because of low percentage of relapses...
  60. ncbi Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers
    W Ridtitid
    Department of Pharmacology, Faculty of Science, Prince of Songkla University, Hat Yai, Thailand
    J Pharm Pharmacol 52:1265-9. 2000
    ..Quinine is mainly metabolized by the cytochrome P450 3A4 isozyme (CYP3A4), whereas rifampin, a potent inducer of CYP3A4, is known to markedly decrease plasma quinine concentration...
  61. ncbi Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects
    Kelly E Dooley
    Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    J Acquir Immune Defic Syndr 62:21-7. 2013
    Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of drug metabolizing enzymes...
  62. pmc Antimicrobial drug resistance affects broad changes in metabolomic phenotype in addition to secondary metabolism
    Dagmara K Derewacz
    Department of Chemistry, Vanderbilt University, Nashville, TN 37204, USA
    Proc Natl Acad Sci U S A 110:2336-41. 2013
    ..Taken together, these data suggest that biosynthetic pathway derepression is a general consequence of some antibiotic resistance mutations...
  63. pmc Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis
    Deepak Almeida
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 53:4178-84. 2009
    To investigate the antagonism between isoniazid (INH) and rifampin (rifampicin) (RIF)-pyrazinamide (PZA) combination observed in Mycobacterium tuberculosis-infected mice, extensive pharmacokinetic studies of INH were performed and ..
  64. pmc Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis
    Ian M Rosenthal
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 56:4331-40. 2012
    In previous experiments, replacing the 10-mg/kg of body weight daily dose of rifampin with 7...
  65. pmc Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009
    M Gegia
    The National Center for TB and Lung Diseases, Georgia, Tbilisi, Georgia
    Int J Tuberc Lung Dis 16:812-6. 2012
    ..The current daily 9-month regimen of rifampin, pyrazinamide and ethambutol was established based largely on trials in settings with low TB rates and low rates ..
  66. ncbi Mycothiol: a target for potentiation of rifampin and other antibiotics against Mycobacterium tuberculosis
    Marcy Hernick
    Department of Biochemistry, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA
    Expert Rev Anti Infect Ther 11:49-67. 2013
    ....
  67. pmc Antimicrobial-resistant strains of Clostridium difficile from North America
    Fred C Tenover
    Cepheid, Sunnyvale, California, USA
    Antimicrob Agents Chemother 56:2929-32. 2012
    ..from patients in North America were screened for resistance to clindamycin, metronidazole, moxifloxacin, and rifampin. Clindamycin resistance was observed among 16 different ribotypes, with ribotypes 017, 053, and 078 showing the ..
  68. ncbi Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol
    K P Kanebratt
    Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden
    Clin Pharmacol Ther 84:589-94. 2008
    ..4-fold, P < 0.05; and 4.2-fold, P < 0.01, respectively). In conclusion, we have shown that the Karolinska cocktail and 4beta-hydroxycholesterol can be used for an initial screening of the induction properties of a drug candidate...
  69. pmc Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin
    R Rossau
    Innogenetics NV, Ghent, Belgium
    Antimicrob Agents Chemother 41:2093-8. 1997
    Mycobacterium tuberculosis resistance to rifampin results from nucleotide changes in the gene encoding the beta-subunit of the RNA polymerase (rpoB). We developed a reverse hybridization-based line probe assay (LiPA; the INNO-LiPA Rif...
  70. pmc Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model
    Marie Therese Ruf
    Swiss Tropical and Public Health Institute, Basel, Switzerland
    Antimicrob Agents Chemother 56:687-96. 2012
    Combination chemotherapy with rifampin and streptomycin (RIF-STR) for 8 weeks is currently recommended by the WHO as the first-line treatment for Mycobacterium ulcerans infection (Buruli ulcer)...
  71. pmc Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study
    Anne F Luetkemeyer
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 57:586-93. 2013
    b>Rifampin (RIF) upregulates CYP 450 isoenzymes, potentially lowering efavirenz (EFV) exposure. The US EFV package insert recommends an EFV dose increase for patients on RIF weighing ≥50 kg...
  72. ncbi Characterization of the termination phenotypes of rifampicin-resistant mutants
    D J Jin
    Department of Bacteriology, University of Wisconsin, Madison 53706
    J Mol Biol 202:245-53. 1988
    ..Only two Rifr mutations suppress the termination defect of rho15 strains. We discuss models to explain how this region of the beta polypeptide might be involved in the process of transcription termination...
  73. pmc In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans
    Baohong Ji
    Bactériologie Hygiène, Faculte de Medecine Pierre et Marie Curie, Universite Paris 6, France
    Antimicrob Agents Chemother 50:1921-6. 2006
    ..R207910 demonstrated the lowest MIC(50) and MIC(90), followed by moxifloxacin (MXF), streptomycin (STR), rifampin (RIF), amikacin (AMK), linezolid (LZD), and PA-824...
  74. ncbi Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance
    H Traore
    Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium
    Int J Tuberc Lung Dis 4:481-4. 2000
    ..This approach must therefore be validated in each local situation...
  75. ncbi Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan
    S Hofmann-Thiel
    IML, Institute of Microbiology and Laboratory Medicine, Supranational Reference Laboratory SNRL, Asklepios Fachkliniken, Robert Koch Allee 2, D 82131 Gauting, Germany
    Eur Respir J 33:368-74. 2009
    ..Hain Lifescience, Nehren, Germany), which is designed to detect genetic mutations associated with resistance to rifampin and isoniazid...
  76. pmc Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans
    S Etuaful
    St George s Hospital Medical School, Department of Cellular and Molecular Medicine, Cranmer Terrace, London SW17 0RE, United Kingdom
    Antimicrob Agents Chemother 49:3182-6. 2005
    ..Lesions were excised either immediately or after treatment with rifampin orally at 10 mg/kg of body weight and streptomycin intramuscularly at 15 mg/kg of body weight daily for 2, 4, 8, ..
  77. ncbi Inconsistent dosing of anti-tuberculosis drugs in Taipei, Taiwan
    C Y Chiang
    International Union Against Tuberculosis and Lung Disease, Paris, France
    Int J Tuberc Lung Dis 14:878-83. 2010
    ..Taipei City, Taiwan...
  78. ncbi The K+ uptake regulator TrkA controls membrane potential, pH homeostasis and multidrug susceptibility in Mycobacterium smegmatis
    Alfredo Castañeda-García
    Centro Nacional de Biotecnologia CSIC, Darwin 3, Campus de la Universidad Autonoma, Cantoblanco, Madrid 28049, Spain
    J Antimicrob Chemother 66:1489-98. 2011
    ..Although most rifampicin-resistant strains arise through mutations in the rpoB gene in bacteria, a proportion of such strains show no rpoB mutations. This suggests that alternative mechanisms are responsible for rifampicin resistance...
  79. ncbi Treatment of human brucellosis with rifampin plus minocycline
    A Cascio
    AILMI Associazione Italiana per la Lotta contro le Malattie Infettive c o Scuola di Specializzazione in Malattie Infettive Università di Messina, Via Consolare Valeria n 1, 98125 Messina, Italy
    J Chemother 15:248-52. 2003
    In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 ..
  80. ncbi The RNA polymerase-binding protein RbpA confers basal levels of rifampicin resistance on Streptomyces coelicolor
    Katy V Newell
    Department of Biochemistry, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9QG, UK
    Mol Microbiol 60:687-96. 2006
    ..The data presented suggest that RbpA confers basal levels of rifampicin resistance and is a novel regulator of rRNA synthesis in S. coelicolor...
  81. pmc Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin
    Sébastien Lefrançois
    Laboratoire de Bacteriologie Hygiene, Faculte de Medecine Pierre et Marie Curie, Universite Paris 6, and CNRM et de la Résistance aux Antituberculeux, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hôpital de Paris, France
    Antimicrob Agents Chemother 51:645-50. 2007
    The curing activities of various durations of treatment with a combination of rifampin (RIF) and either streptomycin (STR) or amikacin (AMK) in murine Mycobacterium ulcerans infection were compared in two experiments...
  82. pmc Molecular characterization of resistance to Rifampicin in an emerging hospital-associated Methicillin-resistant Staphylococcus aureus clone ST228, Spain
    Virginie Mick
    Microbiology Department, Hospital Universitari de Bellvitge, University of Barcelona, IDIBELL, Feixa Llarga s n 08907 Hospitalet de Llobregat, Barcelona, Spain
    BMC Microbiol 10:68. 2010
    ....
  83. ncbi Chemotherapy and diagnosis of tuberculosis
    Cesare Saltini
    Department of Internal Medicine, University of Roma Tor Vergata, Viale Oxford 81, 00133 Roma, Italy
    Respir Med 100:2085-97. 2006
    ....
  84. pmc New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 54:1484-91. 2010
    ..The critical concentration of isoniazid is either 0.2 or 1.0 mg/liter, that of rifampin is 1.0 mg/liter, that of pyrazinamide is 100 mg/liter, that of ethambutol is 5...
  85. pmc Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux
    Gail E Louw
    Department of Biomedical Sciences, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa
    Am J Respir Crit Care Med 184:269-76. 2011
    ..Central dogma suggests that rifampicin resistance in Mycobacterium tuberculosis develops solely through rpoB gene mutations...
  86. ncbi Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis
    Gilman Kit Hang Siu
    Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital, Hong Kong Special Administrative Region, China
    J Antimicrob Chemother 66:730-3. 2011
    ..Our study aims to identify the mutations outside the RRDR that are associated with rifampicin resistance in M. tuberculosis...
  87. pmc Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates
    M Heep
    Institut fuer Medizinische Mikrobiologie und Hygiene, , Regensburg, Germany
    J Clin Microbiol 39:107-10. 2001
    The prevalence of recently described mutation V176F, located in the beginning of the rpoB gene and associated with rifampin resistance and the wild-type cluster I sequence, was determined by analyzing the distribution of rpoB mutations ..
  88. ncbi Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting?
    Grant Theron
    Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, Dept of Medicine, University of Cape Town, Cape Town, South Africa
    Eur Respir J 40:161-8. 2012
    ..In MTB/RIF-negative individuals, CXR has poor rule-in value but can reliably rule out TB in approximately one in four cases. These data inform upon the programmatic utility of MTB/RIF in high-burden settings...
  89. pmc Rapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF?
    Daniela E Kirwan
    Department of Infectious Diseases and Immunity, Imperial College London, UK
    Am J Trop Med Hyg 87:197-201. 2012
    ..While awaiting further clarification it seems prudent to slow its implementation among resource-constrained tuberculosis control programs...
  90. pmc Combining PCR with microscopy to reduce costs of laboratory diagnosis of Buruli ulcer
    Dorothy Yeboah-Manu
    Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
    Am J Trop Med Hyg 85:900-4. 2011
    ..This stepwise approach reduced unit cost by more than 50% to $5.41, and the total costs were reduced from $917 to $433...
  91. pmc Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?
    Marie Therese Ruf
    Swiss Tropical and Public Health Institute, Basel, Switzerland
    PLoS Negl Trop Dis 5:e1252. 2011
    ..After the recommended eight weeks standard treatment with rifampicin and streptomycin, a reversal of the local immunosuppression caused by the macrolide toxin mycolactone of M. ulcerans is observed...
  92. pmc Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin
    Anne Kathrin John
    Infectious Diseases Service, Department of Internal Medicine, University Hospital and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland
    Antimicrob Agents Chemother 53:2719-24. 2009
    ..We compared the activity of daptomycin (alone and with rifampin [rifampicin]) with the activities of other antimicrobial regimens against MRSA ATCC 43300 in the guinea pig ..
  93. pmc rpoB Gene mutations and molecular characterization of rifampin-resistant Mycobacterium tuberculosis isolates from Shandong Province, China
    Xin Ma
    Kathearine Hsu Internation REsearch Center of Human Infectious Diseases, Shandong Provinical Tuberculosis Control Center, Jinan, Shandong, China
    J Clin Microbiol 44:3409-12. 2006
    Sixty rifampin (RIF)-resistant and 75 RIF-susceptible Mycobacterium tuberculosis isolates from Shandong Province, China, were analyzed for rpoB gene mutations and genotyped...
  94. ncbi Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin
    Yolande Hauck
    Universite Paris Sud 11, Institut de Genetique et Microbiologie, CNRS, UMR8621, 91405 Orsay, France
    J Antimicrob Chemother 64:259-62. 2009
    ..TB and MTBDRplus, for the identification of mutations in the rpoB hot-spot region and to assess the efficiency of these mutations in conferring resistance to rifampicin...
  95. pmc High frequency of mutations in the rpoB gene in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Singapore
    Ann S G Lee
    J Clin Microbiol 43:2026-7. 2005
  96. ncbi Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions
    D Schutte
    Swiss Tropical Institute, Molecular Immunology, Socinstr 57, 4051 Basel, Switzerland
    Br J Dermatol 160:273-83. 2009
    ..Infection with Mycobacterium ulcerans involves a devastating skin disease called Buruli ulcer (BU). Currently, dual therapy with rifampicin and streptomycin (R/S) for 8 weeks as well as surgery are the standard treatments...
  97. pmc Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin
    Tawanda Gumbo
    Division of Infectious Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:3781-8. 2007
    b>Rifampin is a cornerstone of modern antituberculosis therapy. However, rifampin's half-life of 3 h is believed to limit its utility for intermittent therapy, so new congeners with long half-lives are being developed...
  98. pmc Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection
    Tianyu Zhang
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Am J Respir Crit Care Med 180:1151-7. 2009
    Regimens recommended to treat latent tuberculosis infection (LTBI) are 3 to 9 months long. A 2-month rifampin+pyrazinamide regimen is no longer recommended. Shorter regimens are highly desirable...
  99. pmc Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin
    Hassan Safi
    Division of Infectious Disease and Center for Emerging Pathogens, Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103, USA
    Antimicrob Agents Chemother 52:2027-34. 2008
    ..All parental and isogenic mutant strains had identical isoniazid (INH) and rifampin (RIF) MICs...
  100. ncbi Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs
    Anuj Kumar Gupta
    Department of Microbiology and Molecular Biology, National JALMA Institute for Leprosy and Other Mycobacterial Diseases NJILOMD, Agra, India
    Microb Drug Resist 16:21-8. 2010
    ..Overexpression of two of the genes (Rv2477 and Rv2209) has also been observed with ofloxacin stress in M. tuberculosis...
  101. pmc Transcription modulation of Salmonella enterica serovar Typhimurium promoters by sub-MIC levels of rifampin
    Grace Yim
    Department of Microbiology and Immunology, University of British Columbia, Life Sciences Institute, 2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada
    J Bacteriol 188:7988-91. 2006
    Promoter-lux fusions that showed rifampin-modulated transcription were identified from a Salmonella enterica serovar Typhimurium 14028 reporter library...

Research Grants63

  1. Drug Interactions at the Human Blood-Brain Barrier
    Jashvant D Unadkat; Fiscal Year: 2010
    ..P-gp activity at the human BBB be induced? If so, what is the maximum induction produced by a FDA-approved drug, rifampin, a potent inducer of P-gp (Aim 2)? If P-gp activity at the human BBB is inducible, such a finding would also have ..
  2. Therapeutics for Drug-Resistant Bacteria: Myxopyronins
    Richard H Ebright; Fiscal Year: 2013
    ..of bacterial RNAP in current clinical use in therapy of bacterial infection (the rifamycin antibacterial agents, rifampin, rifapentine, and rifabutin), and exhibits no or minimal cross-resistance with other inhibitors of bacterial RNAP ..
  3. Investigation of synergy between Rifampin and SQ109, a new anti-TB drug candidate
    VENKATA REDDY; Fiscal Year: 2009
    ..Importantly, when used in combination with rifampin (RIF) + isoniazid (INH) + pyrazinamide (PZA), SQ109 is able to increase bacterial killing and reduce the time by ..
  4. Firing up new treatments against Mycobacterium ulcerans disease (Buruli ulcer)
    Jacques H Grosset; Fiscal Year: 2013
    ..ulcerans disease and demonstrated that treatment for two months with amikacin (or streptomycin) and rifampin, used in the mouse at doses equipotent to human doses, was highly active (bactericidal)...
  5. Impact of a New Molecular TB Test on TB/HIV Outcomes among HIV-Infected Malawians
    Richard E Chaisson; Fiscal Year: 2013
    ..tuberculosis complex as well as rifampin resistance...
  6. Impact of TB on Outcome of HIV in Pregnant Women
    Richard E Chaisson; Fiscal Year: 2013
    ..reverse transcriptase inhibitors (NNRTIs) nevirapine and efavirenz because of upregulation of P450 cytochromes by rifampin, the key drug in TB therapy...
  7. The Role of Cell Wall Lipids in Pathogenesis of Rifampin-Resistant TB
    Petros C Karakousis; Fiscal Year: 2013
    ..MDR-TB), defined as Mycobacterium tuberculosis (Mtb) resistant to the two first-line drugs isoniazid and rifampin, has emerged as a major threat to global TB control...
  8. Identifying essential functions in non replicating Mycobacterium tuberculosis
    SARAH S GRANT; Fiscal Year: 2013
    ..PUBLIC RELEVANCE: Despite the use of potent anti-TB agents like isoniazid (INH) and rifampin, the global incidence of tuberculosis has been increasing over the last 25 years, driven by HIV, increasing ..
  9. Improving Pediatric Tb Diagnosis and Management in Tanzania
    Tania A Thomas; Fiscal Year: 2013
    ..including drug-resistant TB, serum drug levels to the two most potent first-line TB medications (isoniazid and rifampin), HIV status, nutritional status and concurrent diarrheal illness...
  10. Molecular Mechanisms Of Daptomycin Resistance In Enterococci
    CESAR AUGUSTO ARIAS; Fiscal Year: 2013
    ..doses of DAP and combination therapies of DAP with i) ampicillin (for VREfs), and ii) with tigecycline or rifampin (for VREfm), in preventing emergence of DAP-R using a murine model of infective endocarditis...
  11. Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant Tuberculosis
    Antonino Catanzaro; Fiscal Year: 2013
    ..e., isoniazid, rifampin, ofloxacin, amikacin, kanamycin, and capreomycin) directly from sputa...
  12. Wirelessly Observed Therapy to Monitor Treatment of Mycobacterium Tuberculosis
    Lorenzo DiCarlo; Fiscal Year: 2013
    ..Phase I proposal focuses on (1) the development and testing of a combination of the Raisin IEM with isoniazid-rifampin therapy (Isonorif");(2) researching and designing user interfaces specifically for MTB patients and healthcare ..
  13. TB Diagnostics at the Point of Care
    CHRISTOPHER GERARD COONEY; Fiscal Year: 2013
    ..simple, and rapid point-of-care (POC) test that detects TB and its resistance to first-line drugs (isoniazid, rifampin, ethambutol,and pyrazinamide) would improve TB diagnostics for these minority communities...
  14. Cross-Border Dynamics of MDR/XDR-TB Epidemiology by HIV Status in Tijuana, Mexico
    Richard Garfein; Fiscal Year: 2009
    ..found 41% of Tijuana's TB cases were resistant to at least one drug and 17% were resistant to isoniazid and rifampin (MDR-TB), universal drug susceptibility testing (DST) was recommended for all TB cases in Mexico, yet is rarely ..
  15. Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
    AWEWURA JACOB KWARA; Fiscal Year: 2013
    ..Aim 1 will determine whether the WHO recommended increased dosages of isoniazid, rifampin, pyrazinamide and ethambutol administered to African children with active TB infection (with or without HIV co- ..
  16. A rapid molecular approach to determine PZA susceptibility
    BARRY NEAL KREISWIRTH; Fiscal Year: 2013
    ..The current TB treatment regimen for TB is 2 months of rifampin, isoniazid, ethambutol and pyrazinamide (PZA), followed by 4 months of rifampin and isoniazid...
  17. ADDICTION THERAPY: METABOLISM AND TRANSPORT-MEDIATED DRUG INTERACTIONS
    Evan D Kharasch; Fiscal Year: 2012
    ..The antitubercular drug rifampin interacts with methadone, but whether this occurs with buprenorphine, and the underlying mechanism(s) for either, ..
  18. Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
    Richard H Ebright; Fiscal Year: 2013
    ..Haemophilus sp., and Moraxella sp. The compound exhibits no cross-resistance with rifampin, the RNAP inhibitor in current use in broad-spectrum antibacterial therapy, and exhibits a spontaneous resistance ..
  19. Concurrent HAART and Tuberculosis Treatment: Drug to Drug Interactions
    AWEWURA JACOB KWARA; Fiscal Year: 2010
    ..the CYP drug metabolizing enzymes and differential modulation of these enzymes by potent enzyme inducers such as rifampin contribute substantially to differences in responses to concurrently administered CYP substrates...
  20. Binational Transmission of Multidrug-Resistant Tuberculosis, California &Mexico
    TIMOTHY CHARLES RODWELL; Fiscal Year: 2012
    ..tuberculosis strains that are resistant to the two most effective anti-TB drugs: isoniazid (INH) and rifampin (RIF). Despite efforts to prevent MDR- TB from occurring in California, there are still 40-50 cases per year...
  21. Optimal dosing of 1st line antituberculosis and antiretroviral drugs in children
    Helen McIlleron; Fiscal Year: 2013
    ..Recent studies suggest that first line anti-TB drugs (isoniazid, rifampin, ethambutol and pyrazinamide) are often under-dosed in adults, especially with HIV, and children...
  22. Plasma and Intrapulmonary Pharmacokinetics and Pharmacodynamics (PKPD) of Aerosol
    Jeffrey Golden; Fiscal Year: 2010
    ..The specific aim of this project is to plan a clinical trial that will administer aerosolized isoniazid (INH), rifampin (RIF) and streptomycin (SM) to healthy volunteers and measure the concentration of each drug in the blood and ..
  23. PHARMACOKINETICS AND TOXICITY OF 2ND LINE ANTI-TB DRUGS IN HIV-INFECTED CHILDREN
    ANNEKE CATHARINA HESSELING; Fiscal Year: 2013
    ..Multidrug-resistant TB (MDR-TB;i.e. resistance to both rifampin and isoniazid) is an emerging epidemic, with an estimated 489 000 global cases annually...
  24. Development of a second generation MDR-XDR TB assay
    David Alland; Fiscal Year: 2013
    ..and mutations required for MTB and mycobacteria other than tuberculosis (MOTT) detection and isoniazid (INH), rifampin (RIF) and fluoroquinolone (FQ) antibiotic resistance testing in a single real-time PCR tube...
  25. Evaluation of a highly-informative LATE-PCR single-tube assay for M(X)DR-TB
    Robin Mark Warren; Fiscal Year: 2013
    ..tuberculosis complex and isoniazid and/or rifampin. These novel assays established a new diagnostic paradigm by using rapid molecular methods that identified ..
  26. Pharmacogenetics and Drug-Drug Interactions during HIV/TB Therapy
    AWEWURA JACOB KWARA; Fiscal Year: 2011
    ..Our hypotheses will be pursued through three specific aims. Aim 1 will test the hypothesis that the effect of rifampin-containing anti-TB therapy on efavirenz plasma pharmacokinetics differs fundamentally among CYP2B6 extensive and ..
  27. Extensively Drug-Resistant Tuberculosis Among Gold Miners in South Africa
    Susan E Dorman; Fiscal Year: 2012
    ..the program of laboratory surveillance will incorporate an evaluation of new rapid tests for detection of rifampin resistance, and provide data relevant to future development of molecular tests for rapid detection of ..
  28. Optimal Drug Regimens for TB: An Integrated Computational/Experimental Approach
    Michael A Lyons; Fiscal Year: 2013
    ..While we seek to establish the feasibility of the proposal using current front-line anti-TB drugs (isoniazid, rifampin, pyrazinamide), the ultimate aim of this project is the application of the methodology to the newer anti-TB drugs ..
  29. Optimizing the impact of Xpert MTB/RIF on treatment outcomes of drug resistant TB
    ANNELIES T A VAN RIE; Fiscal Year: 2013
    ..Using Xpert MTB/RIF, clinicians will need to make a treatment decision based on the knowledge of rifampin resistance only, and thus risk the initiation of a suboptimal regimen...
  30. Antimicrobial pharmacokinetics and outcomes in vulnerable infants
    Matthew Laughon; Fiscal Year: 2013
    ..Fluconazole and rifampin are two antimicrobials commonly used in the nursery for which pharmacokinetic data can be improved. Dr...
  31. Randomized Trial of High-Dose Rifampin in Patients with New Smear-Positive TB
    Carole D Mitnick; Fiscal Year: 2013
    ..provided by applicant): This phase II, randomized, blinded study will evaluate the potential of high doses of rifampin (RIF) to shorten treatment for tuberculosis (TB) in Peru and Brazil...
  32. P-glycoprotein and Alzheimer's Disease
    Jashvant D Unadkat; Fiscal Year: 2010
    ..P-gp is an inducible transporter and several, well-established approved drugs (e.g. rifampin), can induce P-gp activity...
  33. M. AVIUM DISEASE--INHALED LIPOSOME ANTI-TB DRUG THERAPY
    Hans Schreier; Fiscal Year: 1992
    ..alveolar macrophages (AM) and is relatively resistant in vitro to anti-tuberculous drugs such as isoniazid, rifampin, and ethambutol in concentrations currently employed...
  34. Combination Antibotics as a Treatment for Chlamydia-Induced Reactive Arthritis
    John Carter; Fiscal Year: 2007
    ..b>Rifampin has been shown to attenuate Ct HSP production; it also displays synergistic effect with azithromycin in Ct ..
  35. PRECLINICAL DEVELOPMENT OF NEW ANTITUBERCULOSIS REGIMEN
    Leonid Heifets; Fiscal Year: 2000
    ..Regimens targeted against MDR-TB will include substitutes for isoniazid, rifampin, pyrazinamide, streptomycin,ethambutol, developed under this program or already available (for example, some ..
  36. Optimizing NNRTI Doses in Patients with HIV and TB
    Terrence Blaschke; Fiscal Year: 2007
    ..The Department of Health and Human Services recommends the use of rifampin (RMP) with a regimen consisting of one of the non nucleoside reverse transcriptase inhibitors (NNRTI) efavirenz (..
  37. OXYGEN AND SPONTANEOUS MUTAGENESIS IN ESCHERICHIA COLI
    Robert Fowler; Fiscal Year: 1991
    ..genetically well-characterized facultative aerobic bacterium, Escherichia coli, measurement of forward (LacI-, rifampin resistance and valine resistance) and back (TrpA+) mutation frequencies reveal the proportion of spontaneous ..
  38. AGING EFFECT ON DRUG BIOAVAILABILITY
    Stephen Hall; Fiscal Year: 1999
    ..The effect of a CYP3A inhibitor (clarithromycin) and inducer (rifampin) on the intestinal availability, intestinal intrinsic clearance, hepatic availability and hepatic intrinsic ..
  39. EFFICACY OF TB CHEMOPROPHYLAXIS IN PPD, HIV ADULTS
    Jacqueline Coberly; Fiscal Year: 1999
    ..of Cite Soleil (n=345) will be randomized to receive isoniazid and pyridoxine (B6) daily for six months, rifampin and B6 daily for three months followed by daily B6 for three months, or B6 daily for six months...
  40. Target for Mefloquine in Mycobacteria
    Luiz Bermudez; Fiscal Year: 2002
    ..avium strain resistant to macrolides, quinolones, isoniazid, ethambutol and rifampin, suggesting a novel mechanism of action...
  41. E COLI TRANSLOCATION ACROSS INTESTINAL EPITHELIUM
    Michelle Pietzak; Fiscal Year: 2003
    ..In earlier studies, Dr. Pietzak has used strain E44, a spontaneous rifampin resistant mutant of E...
  42. INNOVATIVE APPROACHES TO TUBERCULOSIS CONTROL
    Richard Chaisson; Fiscal Year: 2009
    ..We will randomize 526 patients with pulmonary TB to receive Moxi/rifampin/PZA/ethambutol for 4 months vs. a control regimen of INH/RIF/PZA/EMB for 6 months...
  43. MDR1 IN HUMAN INTESTINE
    Kenneth Lown; Fiscal Year: 1999
    ..hypothesis is based on my preliminary data showing mdr1 is inducible in vitro and in vivo in human intestine by rifampin. In Specific Aim 1, I will identify inducers of mdr1 mRNA and protein in small bowel and colon by treating ..
  44. Anti-Infective Central Venous Catheter
    MICHAEL VIOLANTE; Fiscal Year: 2002
    ..One commercial device that has demonstrated a reduction in infection rates uses a combination of antibiotics (rifampin and minocycline} as the active agents on the catheter surface...
  45. NEW CLASS OF ANTITUBERCULOSIS AMIDES:PRECLINICAL DEVELOP
    Leonid Heifets; Fiscal Year: 2001
    ..It is the inclusion of PZA with isoniazid and rifampin in current treatment regimens that constitutes the basis for 6-month short course therapy for M...
  46. A New Target for Anti-tuberculosis Agents, FAS 1
    John Welch; Fiscal Year: 2003
    ..It is the inclusion of pyrazinamide (PZA), an agent with a unique sterilizing activity, with isoniazid and rifampin (RIF) in current treatment regimens that constitutes the basis for 6-month short course therapy for M...
  47. Treatment Outcomes for Patients with Extensively Drug Resistant Tuberculosis
    MAX O DONNELL; Fiscal Year: 2009
    ..of tuberculosis (TB), extensively drug resistant tuberculosis (XDR-TB) is defined as resistance to Isoniazid, rifampin, fluoroquinolones and one of three injectable second-line anti-TB agents...
  48. Prediction of Drug-Drug Interactions
    Zeruesenay Desta; Fiscal Year: 2007
    ..concentration dependence of the induction of intestinal and hepatic CYP3A enzymes by the prototypical inducer, rifampin. We will use intravenous midazolam to reflect hepatic CYP3A activity and intestinal pinch biopsies to reflect ..
  49. Rapid Susceptibility Testing of MDR M. tuberculosis- Phase II
    MYRON SASSER; Fiscal Year: 2007
    ..35-40% loss of mycolic acids, in susceptible strains, with as little as 20 minutes exposure to the inhibitor, rifampin, ethambutol and pyrazinamide may require up to 72 h for optimal determination...
  50. Molecular mechanism of antibiotic rifampicin action
    Irina Artsimovitch; Fiscal Year: 2006
    ..coli rpoB gene will be used to isolate mutants resistant to different rifamycins (rifamycin SV, rifampin, rifabutin, etc), with the emphasis on the detailed analysis of mutants conferring differential resistance as the ..
  51. GENETIC LINKAGE RELATIONS OF NEISSERIA GONORRHOEAE
    ELIZABETH SHINNERS; Fiscal Year: 1991
    ..A specific region which links genes for arginine and pyrimidine synthesis, argA-pyrE-pyrB, to the rif (rifampin resistance) locus on the established map of N...
  52. DEVELOPMENT OF NOVEL PHARMACOPHORE WITH ANTI-TB ACTIVITY
    Ze Qi Xu; Fiscal Year: 2001
    ..demonstrated that it was active against Mycobacterium tuberculosis strains resistant to isoniazid, rifampin, streptomycin, and ethambutol, respectively...
  53. IMMUNOLOGY AND IMMUNOTHERAPY OF LEPROSY
    James Krahenbuhl; Fiscal Year: 1990
    ..leprae- infected nu/nu mice, an animal model for lepromatous leprosy and correlate our findings with changes in lepromatous macrophage function observed during long term chemotherapy with rifampin and immunotherapy with interferon gamma.
  54. DRY POWDER COATINGS FOR IMPROVED TUBERCULOSIS THERAPIES
    James Talton; Fiscal Year: 2000
    ..parameters involved in this PLD technique to enhance the incorporation of two model drugs (isoniazid and rifampin) into polymeric coated particles and test the dissolution rate, cell toxicity and activity in cell culture with ..
  55. MALABSORPTION OF ANTITUBERCULOUS DRUGS IN BOTSWANA
    Philip Hopewell; Fiscal Year: 1999
    ..Baseline, clinical, microbiologic, and laboratory data, including HIV serologies and serum for isoniazid (H), rifampin (R), ethambutol (E), and pyrazinamide (P) concentrations will be obtained...
  56. HEPATIC DRUG TRANSPORTERS IN DRUG DISPOSITION
    Dan Roden; Fiscal Year: 2006
    ..in human subjects using the well-known OATP-C-specific substrate, pravastatin, and a newly identified substrate, rifampin, as in vivo probes for this transporter...
  57. Randomized Trial of High-Dose Rifampin in Patients with New, Smear-Positive TB
    Carole Mitnick; Fiscal Year: 2007
    ..provided by applicant): This R34 will support preparation for a multi-site Phase II trial of high-dose rifampin (RIF)...
  58. Antibacterial RNA Polymerase Inhibitors
    Christopher Self; Fiscal Year: 2002
    ..Inhibition of bacterial RNAP is known to be an effective antibacterial strategy, but current agents (e.g., rifampin) are toxic and induce resistant strains via binding to a highly variable site of RNAP...
  59. Development of System for Treatment of Tuberculosis
    Takuji Tsukamoto; Fiscal Year: 2001
    ..we will use microparticles to target the delivery of enzyme-cleavable lipophilic derivatives of isoniazid and rifampin to infected macrophages...
  60. Sample Processing Cartridges for Rapid PCR TB Detection
    David Alland; Fiscal Year: 2002
    ..tuberculosis and detects resistance to rifampin directly from clinical sputum samples...
  61. Direct Detection of Drug Resistant Mtb without PCR
    Whei Kuo Wu; Fiscal Year: 2002
    ..Resistance to rifampin, a first-line antituberculosis drug, is almost always the result of mutations in the rpoB gene of the pathogen...
  62. Treatment of Latent TB and MDR-TB with FAS20013
    ALBERT OWENS; Fiscal Year: 2006
    ..equally well that have been adapted to an hypoxic existence (the Wayne model of latency) in contrast to INH and rifampin that are essentially inactive...
  63. M TUBERCULOSIS STRAIN GENOTYPING BY MASS SPECTROMETRY
    DANIEL LITTLE; Fiscal Year: 2000
    ..spectrometry developed at Sequenom Inc to determine whether this platform is amenable to rapid genotyping of rifampin resistance in M. tuberculosis...